Potentiation of μ‐opioid receptor‐mediated signaling by ketamine
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
J. Neurochem.(2011)119, 294–302. Ketamine, a clinically relevant drug, has been shown to enhance opioid‐induced analgesia and prevent hyperalgesia. However, the molecular mechanisms involved are not clearly understood. As previous studies found that activation of opioid receptors leads to the phosphorylation of mitogen‐activated protein kinases, we investigated whether ketamine could modulate μ‐opioid receptor (μOR)‐mediated ERK1/2 phosphorylation. We find that acute treatment with ketamine enhances (∼2‐ to 3‐fold) the levels of opioid‐induced ERK1/2 phosphorylation in recombinant as well as cells endogenously expressing μOR. Interestingly, we find that in the absence of ketamine ERK1/2 signaling is desensitized 10 min after opioid exposure whereas in its presence significant levels (∼3‐fold over basal) are detected. In addition, ketamine increases the rate of resensitization of opioid‐mediated ERK1/2 signaling (15 min in its presence vs. 30 min in its absence). These results suggest that ketamine increases the effectiveness of opiate‐induced signaling by affecting multiple mechanisms. In addition, these effects are observed in heterologous cells expressing μOR suggesting a non‐NMDA receptor‐mediated action of ketamine. Together this could, in part, account for the observed effects of ketamine on the enhancement of the analgesic effects of opiates as well as in the duration of opiate‐induced analgesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“…it also exhibits non-NMDA-mediated effects by modulating the activity of nicotinic (Scheller et al. 1996), muscarinic (Hustveit et al. 1995), opioid (Smith et al. 1980; Finck and Ngai 1982; Hustveit et al. 1995; Hirota et al. 1999) as well as AMPA receptors (Li et al. 2010; Zarate et al. 2010).”
BackgroundLong-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine
Célèrier, E., Rivat, C., Jun, Y., Laulin, J.-P., Larcher, A., Reynier, P., & Simonnet, G. (2000) · Anesthesiology · doi:10.1097/00000542-200002000-00029 · Cited by 584 · cited 4×
“This is thought to be due to the induction of NMDA-dependent central sensitization processes (Laulin et al. 1998; Celerier et al. 2000) because it has been shown that intrathecal morphine causes a large increase in glutamate release (Stiller et al. 1998).”
BackgroundInfluentialInteraction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, σ and Muscarinic Receptors
Hustveit, O., Maurset, A., & Øye, I. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb01041.x · Cited by 246
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time
Laulin, J., Larcher, A., Célèrier, E., Moal, M. L., & Simonnet, G. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00083.x · Cited by 156
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Ketamine – More mechanisms of action than just NMDA blockade
Sleigh, J., Harvey, M., Voss, L., & Denny, B. (2014) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2014.03.002 · Cited by 434
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“Furthermore, whereas ketamine enantiomers are known non-competitive antagonists at NMDARs [19,20], their mode of action at MOR and KOR is not well established [19, 21, 23].”
BackgroundMiller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Metadata
- Authors
- Gupta, A., Devi, L. A., & Gomes, I.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-09-20
- Volume
- 119
- Issue
- 2
- Pages
- 294-302
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1586476523
- Cited by
- 132
- References
- 5
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentiation of μ‐opioid receptor‐mediated signaling by ketamine. https://app.cochat.ai/papers/10.1111/j.1471-4159.2011.07361.x
- The paper
- Gupta, A., Devi, L. A., & Gomes, I. (2011). Potentiation of μ‐opioid receptor‐mediated signaling by ketamine. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2011.07361.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.